Nimotuzumab and gemcitabine in the treatment of pancreatic cancer and splenic metastases
Keywords:
pancreas adenocarcinoma, nimotuzumab, gemcitabineAbstract
A 69-year-old male patient presented with extrahepatic cholestasis, weight loss, asthenia and anorexia, a history of chronic pancreatitis, diabetes mellitus and arterial hypertension, who was diagnosed with adenocarcinoma of the pancreas with splenic metastases. A cholecystojejunostomy was performed with jejunum jejunostomy because the tumor was unresectable. It was included in the IIC RD-EC166 clinical trial and treated with nimotuzumab and gemcitabine. In the evolutionary studies the metastatic images that were observed before the treatment were not appreciated, which presupposes the usefulness of these drugs for their control. No references on the subject were found in the national and international literature consulted.
Downloads
Download data is not yet available.
References
1. Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol [en línea]. 2016 [citado 12 Sep 2019]; 22:9694-9705. DOI: 10.3748/wjg.v22.i44.9694
2. Abrams MJ, Rakszawski K, Vasekar M, Passero F, Jia AA, Saif MW. Recent advances in pancreatic cancer: updates and insights from the 2015 annual meeting of the American Society of Clinical Oncology. Ther Adv Gastroenterol [en línea]. 2016 [citado 12 Sep 2019]; 9:141–151. DOI: 10.1177/1756283X15622601
3. Lam KY, Tang V. Metastatic tumors to the spleen. A 25-Year clinicopathologic study. Arch Pathol Lab Med [en línea]. 2000 [citado 12 Sep 2019]; 124:526-530. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/10747308
4. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin [en línea]. 2017 [citado 12 Sep 2019]; 67:7-30. DOI: 10.3322/caac.21387
5. Mitsimponasa N, Mitsogiannia M, Crespoa F, Hartmann KA, Diederichc S, Klosterhalfend B, Giagounidisa A. Isolated Splenic Metastasis from Non-Small-Cell Lung Cancer: A Case Report and Review of the Literature. Case Rep Oncol [en línea]. 2017 [citado 12 Sep 2019]; 10:638-643. DOI: 10.1159/000478002
6. Abrams HL. The incidence of splenic metastasis of carcinoma. Calif Med [en línea]. 1952 [citado 12 Sep 2019]; 76:281-282. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/14925830
7. Nash D, Sampson CC. Secondary carcinoma of the Spleen. Its Incidence in 544 Cases and a Review of the Literature. J Nat Med Assoc [en línea]. 1966 [citado 12 Sep 2019]; 58:442-446. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/5979365
8. Ramakrishnan MS, Eswaraiah A, Crombet T, Piedra P, Saurez G, Iyer H, Arvind AS.Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. Landes Bioscience [en línea]. 2009 [citado 18 Jun 2019]; 1(1):41-48. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2715181/pdf/mabs0101_0041.pdf
9. Cuba. Ministerio de Salud Pública. NIMOTUZUMAB. Formulario Nacional de Medicamentos. Disponible en: http://fnmedicamentos.sld.cu/index.php?P=FullRecord&ID=173
10.Cuba. Ministerio de Salud Pública. CIMAher® (Nimotuzumab). Resumen de las Características del Producto. CECMED. Disponible en: http://www.cecmed.cu/sites/default/files/adjuntos/rcp/biologicos/rcp_cimaher_2015-08-10_0.pdf
11.Gemcitabina. Chemocare.com [citado 27 May 2019]. Disponible en: http://chemocare.com/es/chemotherapy/drug-info/gemcitabina.aspx
2. Abrams MJ, Rakszawski K, Vasekar M, Passero F, Jia AA, Saif MW. Recent advances in pancreatic cancer: updates and insights from the 2015 annual meeting of the American Society of Clinical Oncology. Ther Adv Gastroenterol [en línea]. 2016 [citado 12 Sep 2019]; 9:141–151. DOI: 10.1177/1756283X15622601
3. Lam KY, Tang V. Metastatic tumors to the spleen. A 25-Year clinicopathologic study. Arch Pathol Lab Med [en línea]. 2000 [citado 12 Sep 2019]; 124:526-530. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/10747308
4. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin [en línea]. 2017 [citado 12 Sep 2019]; 67:7-30. DOI: 10.3322/caac.21387
5. Mitsimponasa N, Mitsogiannia M, Crespoa F, Hartmann KA, Diederichc S, Klosterhalfend B, Giagounidisa A. Isolated Splenic Metastasis from Non-Small-Cell Lung Cancer: A Case Report and Review of the Literature. Case Rep Oncol [en línea]. 2017 [citado 12 Sep 2019]; 10:638-643. DOI: 10.1159/000478002
6. Abrams HL. The incidence of splenic metastasis of carcinoma. Calif Med [en línea]. 1952 [citado 12 Sep 2019]; 76:281-282. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/14925830
7. Nash D, Sampson CC. Secondary carcinoma of the Spleen. Its Incidence in 544 Cases and a Review of the Literature. J Nat Med Assoc [en línea]. 1966 [citado 12 Sep 2019]; 58:442-446. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/5979365
8. Ramakrishnan MS, Eswaraiah A, Crombet T, Piedra P, Saurez G, Iyer H, Arvind AS.Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. Landes Bioscience [en línea]. 2009 [citado 18 Jun 2019]; 1(1):41-48. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2715181/pdf/mabs0101_0041.pdf
9. Cuba. Ministerio de Salud Pública. NIMOTUZUMAB. Formulario Nacional de Medicamentos. Disponible en: http://fnmedicamentos.sld.cu/index.php?P=FullRecord&ID=173
10.Cuba. Ministerio de Salud Pública. CIMAher® (Nimotuzumab). Resumen de las Características del Producto. CECMED. Disponible en: http://www.cecmed.cu/sites/default/files/adjuntos/rcp/biologicos/rcp_cimaher_2015-08-10_0.pdf
11.Gemcitabina. Chemocare.com [citado 27 May 2019]. Disponible en: http://chemocare.com/es/chemotherapy/drug-info/gemcitabina.aspx
Downloads
Published
2019-09-20
How to Cite
1.
Piriz Momblant A, Soler Cano D, Herrera Puente A. Nimotuzumab and gemcitabine in the treatment of pancreatic cancer and splenic metastases. Rev Inf Cient [Internet]. 2019 Sep. 20 [cited 2025 Apr. 22];98(4):515-23. Available from: https://revinfcientifica.sld.cu/index.php/ric/article/view/2323
Issue
Section
Case Reports
